FDA Blocks Mesoblast Cell Therapy Again, Asks for More Data

[cafead]

via The FDA has rejected Mesoblast Limited’s application for its investigational immunomodulator remestemcel-L, which it was proposing as a treatment for pediatric steroid-refractory acute graft versus host disease, the company announced Friday.

article source